HOB Biotech Group, a company specialized in IVD (in vitro diagnostic) reagents for improvement of allergy and autoimmune disease patient care, made its debut at STAR Market, the science and technology innovation board of Shanghai Stock Exchange (SSE), on Jan 13, with an IPO valued at RMB 610 million.
With 118 registered products, including 41 patented ones and 52 with European Union’s CE marking, the company is the ninth STAR Market-listed company and the 45th publicly traded one in SIP.
According to the company, the raised fund will be mainly used to enhance its manufacturing, R&D and marketing capacities, build an IVD reagents R&D center, and support the development of products for diagnosis of autoimmune diseases and allergies.
January 13, 2021
